Drug Profile


Alternative Names: Anti-CD20 monoclonal antibody - Novartis; Arzerra; GSK-1841157; HuMax CD20; OMB-157

Latest Information Update: 04 Feb 2017

Price : $50

At a glance

  • Originator Genmab
  • Developer Genmab; GlaxoSmithKline; Mundipharma International; National Cancer Centre (Singapore); Novartis; Roswell Park Cancer Institute; University Health Network
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action CD20 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia
  • Phase III Diffuse large B cell lymphoma; Follicular lymphoma; Multiple sclerosis
  • Phase II MALT lymphoma
  • Suspended Neuromyelitis optica
  • Discontinued Pemphigus vulgaris; Rheumatoid arthritis; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 28 Jan 2017 GlaxoSmithKline completes a phase-II trial in MALT lymphoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy (IV) (EudraCT2011-003495-36)
  • 12 Dec 2016 Registered for Chronic lymphocytic leukaemia (Second-line therapy or greater, Combination therapy) in Liechtenstein, Iceland, European Union, Norway (IV)
  • 10 Nov 2016 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of ofatumumab for Chronic lymphocytic leukaemia (Second line therapy, Combination therapy) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top